Alzheimer’s Drug Discovery Foundation (ADDF): ADDF/AFTD Novel Biomarkers to Accelerate Drug Discovery for Frontotemporal Dementias

Letter of Intent. Drug discovery for frontotemporal dementias (FTD) and spectrum disorders has been hindered by the heterogeneity of the disease. FTD-specific biomarkers that reflect pathological and clinical differences are needed to select appropriate patients for clinical trials and monitor responses to investigational treatments. The Alzheimer’s Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) challenge scientists to meet this unmet medical need by submitting applications through this Request for Proposals (RFP).
The ADDF and AFTD are particularly interested in:
• Defining and validating clinical outcomes for FTD subpopulations for use in clinical trials
• FTD-relevant imaging agents
• CSF- and plasma-based assays
• TDP-43 and tau-focused biomarkers specifically relevant to FTD populations.
Funding up to $150K for 1 year, with the possibility of follow-on funding.